The projects address breast, lung, colon, prostate and melanoma cancer.
The newspaper “La Opinión de Zamora” has published an article devoted to breast cancer, one of the tumours most widely diagnosed in women in Spain and one of the most lethal.
The newspaper is organising a conference on breast cancer on 18 October, to which Angel R. Nebreda, ICREA researcher at IRBBarcelona, has been invited. The scientist will explain the breakthroughs achieved in basic research that can contribute to personalised treatments. Recently, Nebreda’s lab published a paper in the journal Cancer Cell reporting on a mechanism that prevents tumour...
El Punt Avui and La Vanguardia have published an article about the European Research Council (ERC) Proof of Concept grants. Five of them were given to centres belonging to the Barcelona Institute of Science and Technology (BIST), two corresponding to researchers Eduard Batlle and Angel R. Nebreda at IRB Barcelona.
Link to La Vanguardia: España, líder en la última convocatoria de ciencia europea (in Spanish)
Link to El Punt Avui:...
IRB Barcelona has been awarded two ERC PoC grants to optimise and validate tools with potential clinical applications.
Angel R. Nebreda’s project seeks to develop treatments to reduce the cardiotoxicity caused by chemotherapy.
Eduard Batlle’s project will build a biobank of mouse tumour organoids with the aim to contribute to the treatment of patients with advanced colon cancer.
Like many other great discoveries made in science, chance played an important role in the last article published in Cancer Cell by a team of researchers from the Signalling and Cell Cycle Laboratory at IRB Barcelona. "I think we were lucky, but we also knew how to take advantage of our luck," says the biochemist Begoña Cánovas, co-first author of the article, together with Ana Igea.
This success story started back in 2011 when Angel R. Nebreda’s Signalling and Cell Cycle Laboratory moved from CNIO (Madrid) to IRB Barcelona. Among many other things (from big machines to tiny gene copies), they brought with them some mice that were about to be discarded. They had been...
La Razón, Al Día, Cope, Medical News Today, Medical Xpress, among other national and international media, have published articles about the research led by Angel R. Nebreda, head of the Cell Signalling and Cell Cycle Lab at IRB Barcelona. This study identifies a new mechanism that contributes to the development of inflammation-associated colon cancer and proposes new therapeutic approaches.
Link to Al Día
A new study by researchers at IRB Barcelona demonstrates that myeloid cells, which belong to the leucocyte family and form part of the innate immune system, use p38 protein signalling to support inflammation-associated colon cancer.
Published in EMBO Molecular Medicine, the study by Angel R. Nebreda suggests that inhibition of the p38 pathway in myeloid cells may be a useful therapeutic approach, especially in tumours associated with chronic inflammation.
This weekend the Ciutadella Park will be hosting this event, which will showcase 230 scientific activities aimed at the general public.
IRB Barcelona will be participating through two workshops and a micro-talk, related to microscopy, cancer research and ageing.
La Voz de Galicia, TV3, 8TV, among other media, have interviewed Begoña Cánovas, the first author of a recent study led by IRB Barcelona and published in the journal Cancer Cell. The study identifies the key role of p38 in safeguarding tumour cells against the excessive accumulation of DNA damage, which would otherwise cause cell death.
Link to TV3
Link to 8TV
El País, Ara, La Razón, El Economista, Medical Xpress, News-Medical, among other national and international media, have published an article about recent research led by IRB Barcelona, which reveals a new protective mechanism for tumour cells in breast cancer and identifies novel therapeutic targets to treat this disease.
Link to El País
Link to El Economista